Global R&D Pipeline
My Favorite
Hot Targets:
FcRn
Back
Total number of drugs
35
Phase II and later clinical stages
14.3%
Involving companies
75
Main therapeutic areas
Nervous System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rozanolixizumab | Rozanolixizumab | Monoclonal antibody | Neoplasms Immune System Diseases Nervous System Diseases Hemic and Lymphatic Diseases Other Diseases Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Cardiovascular Diseases | FcRn antagonists Immunomodulators | UCB SA | UCB Biopharma SRL UCB Pharma GmbH UCB SA UCB Pharma Ltd. UCB, Inc. UCB Trading (Shanghai) Co., Ltd. UCB Japan Co. Ltd. NYU Langone Medical Center UCB Korea Co., Ltd. | Approved | Approved | United States China European Union Japan United Kingdom Canada Australia Iceland South Korea Liechtenstein Norway | 2023-06-26 | 2025-03-25 | Orphan Drug（European Union） Orphan Drug（South Korea） Orphan Drug（United States） Priority Review（Japan） Priority Review（United States） Orphan Drug（Japan） | - | - | - | - | Rozanolixizumab | - | - | detail > | |
| Nipocalimab-aahu | Nipocalimab-aahu | Monoclonal antibody | Neoplasms Immune System Diseases Nervous System Diseases Other Diseases Congenital Disorders Eye Diseases Hemic and Lymphatic Diseases Mouth and Tooth Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | FcRn antagonists Immunomodulators | Janssen Biotech, Inc. | Johnson & Johnson (China) Investment Ltd. Janssen Research & Development LLC Janssen-Cilag International NV Janssen Pharmaceutical KK Janssen Biotech, Inc. | Approved | NDA/BLA | United States Japan | 2025-04-29 | - | Breakthrough Therapy（China） Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United States） Priority Review（China） Priority Review（United States） Rare Pediatric Disease（United States） Orphan Drug（Japan） | - | - | - | - | Nipocalimab-aahu | - | - | detail > | |
| SYN-1436 | SYN-1436 | Synthetic peptide | Immune System Diseases | FcRn antagonists | Bioverativ Therapeutics, Inc. | Bioverativ Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | SYN-1436 | - | - | detail > | |
| KG006 | KG006 | Antibody | Immune System Diseases | FcRn antagonists | Kaigene, Inc. | Kaigene, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | KG006 | - | - | detail > | |
| LIN-2008 | LIN-2008 | Antibody fusion proteins | Neoplasms Nervous System Diseases Other Diseases | FcRn antagonists | Linno Pharmaceuticals Inc. | Linno Pharmaceuticals Inc. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | LIN-2008 | - | - | detail > | |
| VRDN-008 | VRDN-008 | Chemical drugs | Immune System Diseases | FcRn antagonists | Viridian Therapeutics, Inc. | Viridian Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | VRDN-008 | - | - | detail > | |
| 1,4-Naphthoquinone | 1,4-Naphthoquinone | Small molecule drug | Immune System Diseases Skin and Musculoskeletal Diseases | FcRn agonists | Henan Medical University | Henan Medical University | Preclinical | Preclinical | - | - | - | - | - | - | - | - | 1,4-Naphthoquinone | - | - | detail > | |
| LIN-2007 | LIN-2007 | Antibody | Immune System Diseases | FcRn modulators | Linno Pharmaceuticals Inc. | Linno Pharmaceuticals Inc. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | LIN-2007 | - | - | detail > | |
| FcRn(Generian) | FcRn(Generian) | Small molecule drug | Immune System Diseases | FcRn antagonists | Generian Pharmaceuticals, Inc. | Generian Pharmaceuticals, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | FcRn(Generian) | - | - | detail > | |
| Efgartigimod/Hyaluronidase | Efgartigimod/Hyaluronidase | Fc Fragment | Neoplasms Immune System Diseases Nervous System Diseases Other Diseases Congenital Disorders Endocrinology and Metabolic Disease Eye Diseases Hemic and Lymphatic Diseases Mouth and Tooth Diseases Skin and Musculoskeletal Diseases | FcRn antagonists Hyaluronic acid modulators Immunomodulators | argenx BV | Zai Lab (Shanghai) Co., Ltd. argenx SE argenx BV argenx Japan KK | Approved | Approved | United States China Japan | 2023-06-20 | 2024-07-09 | Orphan Drug（United States） Priority Review（China） Priority Review（United States） Orphan Drug（Japan） | - | - | - | - | Efgartigimod/Hyaluronidase | - | - | detail > |
Total 35 data
1
2
3
4
